Rigel Pharmaceuticals annual operating margin
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Rigel Pharmaceuticals's operating margin was 42.63% for fiscal 2025.
View full Rigel Pharmaceuticals company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 42.63% | +29.14 pp |
| 2024 | 2024-12-31 | 13.49% | +31.03 pp |
| 2023 | 2023-12-31 | −17.53% | +28.67 pp |
| 2022 | 2022-12-31 | −46.20% | −37.83 pp |
| 2021 | 2021-12-31 | −8.37% | +18.30 pp |
| 2020 | 2020-12-31 | −26.67% | +89.86 pp |
| 2019 | 2019-12-31 | −116.53% | +46.77 pp |
| 2018 | 2018-12-31 | −163.30% | +1612.26 pp |
| 2017 | 2017-12-31 | −1,775.56% | −1433.40 pp |
| 2016 | 2016-12-31 | −342.15% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 29.95% | −30.14 pp |
| Q1 2026 | 2026-03-31 | 20.21% | −3.74 pp |
| Q4 2025 | 2025-12-31 | 33.19% | +4.28 pp |
| Q3 2025 | 2025-09-30 | 40.91% | +15.50 pp |
| Q2 2025 | 2025-06-30 | 60.09% | +58.88 pp |
| Q1 2025 | 2025-03-31 | 23.95% | +47.54 pp |
| Q4 2024 | 2024-12-31 | 28.92% | +23.42 pp |
| Q3 2024 | 2024-09-30 | 25.41% | +41.28 pp |
| Q2 2024 | 2024-06-30 | 1.21% | +20.80 pp |
| Q1 2024 | 2024-03-31 | −23.59% | +25.22 pp |
| Q4 2023 | 2023-12-31 | 5.49% | +1.44 pp |
| Q3 2023 | 2023-09-30 | −15.87% | +66.25 pp |
| Q2 2023 | 2023-06-30 | −19.59% | +23.89 pp |
| Q1 2023 | 2023-03-31 | −48.81% | +108.11 pp |
| Q4 2022 | 2022-12-31 | 4.05% | +109.00 pp |
| Q3 2022 | 2022-09-30 | −82.12% | +9.72 pp |
| Q2 2022 | 2022-06-30 | −43.48% | +6.20 pp |
| Q1 2022 | 2022-03-31 | −156.92% | −208.46 pp |
| Q4 2021 | 2021-12-31 | −104.94% | −2.90 pp |
| Q3 2021 | 2021-09-30 | −91.84% | −16.90 pp |
| Q2 2021 | 2021-06-30 | −49.68% | +58.88 pp |
| Q1 2021 | 2021-03-31 | 51.54% | +13.83 pp |
| Q4 2020 | 2020-12-31 | −102.04% | +10.53 pp |
| Q3 2020 | 2020-09-30 | −74.94% | −17.23 pp |
| Q2 2020 | 2020-06-30 | −108.56% | +96.49 pp |
| Q1 2020 | 2020-03-31 | 37.71% | +183.29 pp |
| Q4 2019 | 2019-12-31 | −112.58% | +388.35 pp |
| Q3 2019 | 2019-09-30 | −57.71% | +1403.45 pp |
| Q2 2019 | 2019-06-30 | −205.04% | +1778.84 pp |
| Q1 2019 | 2019-03-31 | −145.58% | — |
| Q3 2018 | 2018-09-30 | −500.92% | — |
| Q2 2018 | 2018-06-30 | −1,461.16% | — |
| Q3 2017 | 2017-09-30 | −1,983.89% | — |
Over the last five reported fiscal years, Rigel Pharmaceuticals's operating margin increased from −26.67% to 42.63%, a change of +69.31 percentage points. The latest reported quarter, Q2 2026, shows 29.95%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Rigel Pharmaceuticals filings at SEC.gov ↗